This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Preliminary Findings

Matig R. Mavissakalian, MD; James M. Perel, PhD

Arch Gen Psychiatry. 1989;46(2):127-131.

Abstract
• At the end of a two-week single-blind placebo baseline, 43 patients with a diagnosis of panic disorder with agoraphobia without significant dysphoria-depression and with moderate to severe panic and phobic symptoms were assigned to, and 32 of them completed, a placebo-controlled (n = 7) doseresponse study with three weight-adjusted imipramine hydrochloride dosages: 0.5 mg/kg/d (n =10), 1.5 mg/kg/d (n = 9), and 3 mg/kg/d (n = 6). Eleven patients, three from the medium-dose and eight from the high-dose conditions, dropped out owing to side effects. No instructions or encouragement for selfdirected exposure to phobic situations or other coping strategies with panic or fear were given throughout the trial. Compliance, as assessed by pill counts and by plasma tricyclic levels, was high. Results provided strong evidence for a positive dose-response relationship on panic and phobic symptoms and confirmed earlier suggestions (1) that imipramine without concurrent exposure possesses a significant antipanic and antiphobic effect, (2) that improvement correlates primarily with imipramine but not N-desmethylimipramine plasma levels, and (3) that side effects prevent optimum dose buildup in a substantial proportion of patients with this disorder.

Author Affiliations
From the Department of Psychiatry, College of Medicine, Ohio State University, Columbus (Dr Mavissakalian); and the Clinical Pharmacology Program, School of Medicine, University of Pittsburgh (Dr Perel).

Footnotes
Accepted for publication April 22, 1988.

Reprint requests to Department of Psychiatry, Ohio State University, 473 W 12th Ave, Columbus, OH 43210 (Dr Mavissakalian).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Anticipation of Age at Onset in Panic Disorder
Battaglia et al.
Am. J. Psychiatry 1998;155:590-595.
ABSTRACT | FULL TEXT  

Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
Ballenger et al.
Am. J. Psychiatry 1998;155:36-42.
ABSTRACT | FULL TEXT  

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants
Anderson and Tomenson
J Psychopharmacol 1994;8:238-249.
ABSTRACT  

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder
Black et al.
Arch Gen Psychiatry 1993;50:44-50.
ABSTRACT  

Maintenance Drug Treatment of Panic Disorder: I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine
Schweizer et al.
Arch Gen Psychiatry 1993;50:51-60.
ABSTRACT  

Imipramine in panic disorder. 1. Clinical response and pharmacological changes
Nutt and Glue
J Psychopharmacol 1991;5:56-64.
ABSTRACT